Skip to main content
NanoRepro AG logo

NanoRepro AG — Investor Relations & Filings

Ticker · NN6 ISIN · DE0006577109 LEI · 3912008FCA63AGIMEV74 F Manufacturing
Open in API
Filings indexed 413 across all filing types
Latest filing 2020-12-02 Share Issue/Capital Cha…
Country DE Germany
Listing F NN6

About NanoRepro AG

https://www.nanorepro.com/en/

NanoRepro AG is a company specializing in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The products are designed for both home and professional use. The company's portfolio covers various health areas, including family planning, preventive healthcare, disease detection, food intolerances, allergies, and infectious diseases. The primary goal is to provide accuracy in self-diagnostics for rapid disease detection and health monitoring.

Recent filings

Filing Released Lang Actions
NanoRepro AG: Kapitalerhohung offnet die Tur zu deutlich hoheren Ordervolumina
Share Issue/Capital Change Classification · 99% confidence The document is a news release from NanoRepro AG dated December 2, 2020, announcing a capital increase ('Kapitalerhöhung') to finance larger orders for Corona antigen tests. The key subject is fundraising and changes to the capital structure ('Kapitalerhöhung im Rahmen eines mittelbaren Bezugsrechts'). This directly aligns with the definition for Capital/Financing Update (Code: CAP). Although it is a news release, the core content is the financing action itself, not just an announcement of a report (which would suggest RPA or RNS).
2020-12-02 German
NanoRepro AG gibt weitere Einzelheiten der Barkapitalerhohung mit Bezugsrecht bekannt
Share Issue/Capital Change Classification · 99% confidence The document is a news release from NanoRepro AG dated December 1, 2020, detailing the specifics of a previously announced cash capital increase ('Barkapitalerhöhung mit Bezugsrecht'). Key elements include the increase in share capital, the subscription ratio (3.53:1), the subscription price (€3.03), the subscription period, and the intended use of the net proceeds (financing COVID-19 rapid tests and R&D). This content directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition for Capital/Financing Update (Code: CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report publication (RPA).
2020-12-01 German
NanoRepro AG beschliet Barkapitalerhohung mit Bezugsrecht
Capital/Financing Update Classification · 99% confidence The document is an 'Ad-hoc' announcement dated November 27, 2020, titled 'NanoRepro AG beschließt Barkapitalerhöhung mit Bezugsrecht' (NanoRepro AG resolves cash capital increase with subscription rights). It explicitly discusses the decision to increase the share capital ('Kapitalerhöhung') by issuing new shares and setting a subscription price. This directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it mentions publishing a 'Wertpapier-Informationsblatt' (securities information sheet), the core content is the decision itself, not just the announcement of the report's availability, making CAP more specific than RPA or RNS.
2020-11-27 German
NanoRepro AG: Corona-Antigentest: Erster Groauftrag aus dem Ausland
Share Issue/Capital Change Classification · 99% confidence The document is a short news release dated November 17, 2020, announcing a major foreign order for Corona Antigen Tests received by NanoRepro AG. It details the order size (1 million tests), the customer location (Colombia), and the cumulative order intake (€14.5 million). It is not a comprehensive annual report (10-K), an interim report (IR), or a detailed management discussion (MDA). It is a specific announcement regarding business development and sales figures, which aligns best with an Earnings Release (ER) which covers key highlights of performance/orders, or potentially a Regulatory Filing (RNS) as it is distributed via DGAP. Given the content focuses on a significant sales/order development, ER is a strong candidate. However, since it is a specific business update distributed via a general news service (DGAP) and doesn't contain structured quarterly/periodical financial statements, RNS (Regulatory Filings/General Announcement) serves as a robust fallback for non-standard, material news updates that aren't explicitly defined elsewhere (like DIV, CAP, or ER which usually implies structured results). Since it is a short news item announcing a material event, RNS is appropriate, although ER is plausible if this was the only update for the period. Given the structure and source (DGAP-News), RNS is the most fitting general regulatory announcement category for material news that isn't a full report or specific financial event.
2020-11-17 German
NanoRepro AG: Antigentest-Umsatz steigt rasant
Regulatory Filings Classification · 99% confidence The document is a short news release dated November 3, 2020, titled 'NanoRepro AG: Antigentest-Umsatz steigt rasant' (Antigen Test Sales Rising Rapidly). It reports on recent sales figures (€2.5M in two days, total backlog >€8.5M) for COVID-19 antigen tests and mentions plans to add a fourth supplier. This content focuses on immediate, recent financial performance highlights rather than a comprehensive periodic report (like 10-K or IR) or a formal Q&A transcript (CT). It fits the definition of an initial announcement of periodical financial results or key highlights, which corresponds to the Earnings Release (ER) category. Although it's not explicitly labeled 'Earnings Release,' the content structure (recent sales figures, CEO quote on outlook) strongly suggests this function. Given the short length and focus on immediate results, it is not a full report (10-K, IR). It is also not a general regulatory filing (RNS) because it is clearly focused on financial results updates.
2020-11-03 German
NanoRepro AG: Umsatz mit Antigen-Test uber Plan
Earnings Release Classification · 100% confidence The document is a short news release dated October 30, 2020, from NanoRepro AG, distributed via DGAP-News. It discusses strong sales performance of their antigen tests due to regulatory approval and confirms the previous forecast for the second half of 2020. The content focuses on recent operational and sales highlights, rather than a comprehensive annual report (10-K), a detailed interim report (IR), or a formal transcript (CT). Since it announces key financial/operational results briefly, it fits best as an Earnings Release (ER). It is too specific for a general Regulatory Filing (RNS) and does not fit any other category like management changes (MANG) or dividend notices (DIV). The length (under 5,000 characters) and nature suggest it is an initial announcement of results, not a detailed report. H2 2020
2020-10-30 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.